{"id":186106,"date":"2014-05-08T19:38:00","date_gmt":"2014-05-09T00:38:00","guid":{"rendered":"https:\/\/www.panix.com\/~msaroff\/40years\/2014\/05\/08\/remember-the-that-miracle-hepatitis-b-cure\/"},"modified":"2014-05-08T19:38:00","modified_gmt":"2014-05-09T00:38:00","slug":"remember-the-that-miracle-hepatitis-b-cure","status":"publish","type":"post","link":"https:\/\/www.panix.com\/~msaroff\/40years\/2014\/05\/08\/remember-the-that-miracle-hepatitis-b-cure\/","title":{"rendered":"Remember the that Miracle Hepatitis B Cure?"},"content":{"rendered":"<p>You knwo, the one that costs $1,000.00 a pill, <a href=\"http:\/\/40yrs.blogspot.com\/search?q=sovaldi&amp;max-results=20&amp;by-date=true\">Solvaldi<\/a>?<\/p>\n<p>Well, it turns out that, in addition to being priced at larcenous expensive, the <a href=\"http:\/\/hcrenewal.blogspot.com\/2014\/05\/some-authoritative-skepticism-about.html\">evidence of its efficacy is simply not there<\/a>:<\/p>\n<blockquote><p><span style=\"color: blue;\">The German agency performed this assessment based on a dossier submitted  by the drug manufacturer (presumably Gilead).&nbsp; The assessment found  some reason to think the drug beneficial, but that the evidence was  sparse, left many questions unanswered, and was inadequate to assess the  drug for some important patient populations.&nbsp; At this point, only a <a href=\"https:\/\/www.iqwig.de\/en\/press\/press_releases\/press_releases\/sofosbuvir_indication_of_added_benefit_for_specific_patients.6099.html\">summary<\/a> is available in English.&nbsp; It includes links to further information in German.<\/p>\n<p>\u2026\u2026\u2026<\/p>\n<p>Thus the assessment concluded that the drug company dossier included at best irrelevant data that it tried to pass off  as important, and inexplicably left out other data that might have been relevant. <\/p>\n<p>\u2026\u2026\u2026<\/p>\n<p><b>Summary<\/b><\/span><br \/><span style=\"color: blue;\"><br \/><\/span> <\/p>\n<div style=\"background-color: white; border: medium none; overflow: hidden; text-align: left; text-decoration: none;\"><span style=\"color: blue;\">It is even bloodier money if the assumption that the drug is a  &#8220;well-tolerated and effective cure,&#8221; which&nbsp; Dr Huyler held, proves not  to be true.&nbsp; It is clear that most of the money that Gilead is now  scooping up in the US is not to pay retrospectively for research and  development or drug production. Instead, it seems likely to be  supporting marketing, public relations, some investors&#8217; profits, and  huge executive compensation.&nbsp; When the public realizes that the money  may not be buying miracles, the outrage should increase.&nbsp;&nbsp;<\/span><\/div>\n<p><span style=\"color: blue;\"><br \/><\/span> <span style=\"color: blue;\">The Sovaldi case is a signal example of how our health care system is  awash in marketing hype and public relations buzz that has swamped  rational skeptical thinking about logic and evidence.&nbsp; That marketing  and PR is ever enriching managers while it will send the rest of us,  health care professionals included, to the poor house.&nbsp; And all the  money we spend will not buy us the promised miracles and triumphs.<\/span><br \/><span style=\"color: blue;\"><br \/><\/span> <span style=\"color: blue;\">True health care reform would revisit the pact society once made with  drug, biotechnology and device companies meant to promote reasonably  priced innovation, but now promoting oligarchy; support transparency and  honesty in clinical research; and challenge how health care managers  can make millions or billions from unproven, and sometimes worthless or  dangerous products.<\/span> <\/p><\/blockquote>\n<p>It also turns out that the study was not double blind.<\/p>\n<p>So the wonder drug may not be any more effective than existing drugs, and it costs a lot more.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>You knwo, the one that costs $1,000.00 a pill, Solvaldi? Well, it turns out that, in addition to being priced at larcenous expensive, the evidence of its efficacy is simply not there: The German agency performed this assessment based on a dossier submitted by the drug manufacturer (presumably Gilead).&nbsp; The assessment found some reason to &hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[970,1013,1150,985,992],"tags":[],"class_list":["post-186106","post","type-post","status-publish","format-standard","hentry","category-corruption","category-drugs","category-public-health","category-regulation","category-statistics"],"_links":{"self":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts\/186106"}],"collection":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/comments?post=186106"}],"version-history":[{"count":0,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts\/186106\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/media?parent=186106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/categories?post=186106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/tags?post=186106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}